Quarterly Report Q2 2017

April 16, 2018

Prometic 2017 Second Quarter Financial Results and Highlights:

  •  $101 million of new 2017 cash inflows closed from debt, equity & corporate transactions
  •  On-going review of plasminogen BLA with the U.S. FDA
  •  48-week clinical data from plasminogen phase 2/3 trial confirms no recurrence of lesions, no safety or tolerability issues observed.
  • Concurrence from the FDA on the design of PBI-4050’s planned phase 2/3 pivotal clinical trial for Idiopathic Pulmonary Fibrosis
  • 24-week clinical data confirm efficacy and safety of PBI-4050 maintained in metabolic syndrome & diabetic patients
Previous Flipbook
Quarterly Report Q3 2017
Quarterly Report Q3 2017

Prometic reports 2017 third quarter highlights and financial results

Next Flipbook
Quarterly Report Q1 2017
Quarterly Report Q1 2017

Prometic reports 2017 first quarter highlights and financial results